We're currently making some changes in the background of our email updates to solve some problems we've been having recently. During our testing phase this may automatically generate some alerts, which will show below, but you can ignore these! If all goes according to plan we will be resuming normal service in the next week…
Although mortality related to psychotropic medications has received much attention in recent years, little is known about the relationship between risk of death and cumulative antipsychotic load, and even less about the relationship between mortality and cumulative exposure to antidepressants or benzodiazepines. The authors examined these relationships using nationwide databases. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
'The research compared modern antidepressants such as paroxetine, citalopram and fluoxetine, with cognitive behavioural therapy (CBT) – a type of talking therapy aimed at helping people change unhelpful ways of thinking and behaving.
It found both treatments worked more or less equally well for the initial treatment of people with moderate to severe depression. However, the study did not say if either treatment was effective at preventing depression from returning at some point in the future or who responds best to which type of treatment.
The authors of the review, which included 11 studies involving 1,511 patients, concluded that people should be offered a choice of treatment.'
'However, when looked at in its overall context, the study found only a small increased risk of a child developing autism spectrum disorder (ASD) – estimated to be less than 1 in 100 (0.72% of all births in this study).'
Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
Accumulating evidence indicates that manic symptoms below the threshold for hypomania (mixed features) are common in individuals with major depressive disorder. This form of depression is often severe and is associated with an increased risk for recurrence, suicide attempts, substance abuse, and functional disability. This study evaluated the efficacy and safety of lurasidone in major depressive disorder with mixed features. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
BPS Blog post. Many health services are moving towards generic (non-branded) medicines as a way to reduce costs. We know that people's expectations about a treatment can influence the effects that treatment has on them. We also know that people expect branded medicines to be more effective and to have fewer side effects than their generic counterparts. A new study in Health Psychology looks at whether a generic painkiller is less 'effective' than its chemically identical branded counterpart.
Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
The advent of second-generation antipsychotics (SGAs) in the 1990s brought optimism that neuroleptic-induced tardive dyskinesia (TD) may become relegated to history. Whether or not this is the case remains inconclusive, and this review aims to compare the risk of TD in older adults treated with first-generation antipsychotics (FGAs) versus SGAs. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library